© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 90584 refers to the quadrivalent dengue vaccine, which is a live attenuated vaccine designed for subcutaneous administration. Unlike immune globulins that offer short-term, passive immunity, this vaccine provides active, long-term immunity. It does so by exposing the recipient's immune system to modified versions of the dengue virus, prompting the body to produce its own antibodies. This immunological response enables the body to "remember" how to generate these antibodies upon future exposure to the dengue virus. Dengue fever, also known as breakbone fever, is a mosquito-borne illness characterized by high fever, rash, and intense muscle and joint pain. In severe cases, it can lead to life-threatening complications such as bleeding and shock. Individuals with a history of dengue infection are at an increased risk for severe disease upon subsequent infections. The quadrivalent dengue vaccine specifically targets the four serotypes of the dengue virus, known as DENV 1-4, and is administered in a two-dose schedule, with doses given three months apart. It is important to note that this code is used solely to report the vaccine product itself, while the administration of the vaccine should be reported separately.
© Copyright 2025 Coding Ahead. All rights reserved.
The quadrivalent dengue vaccine is indicated for individuals who are at risk of dengue virus infection, particularly in areas where dengue fever is endemic. The vaccine is recommended for those who may be exposed to the dengue virus through mosquito bites, especially in regions with a high incidence of the disease. It is particularly important for individuals who have had a previous dengue infection, as they are at a greater risk of experiencing severe disease upon re-exposure to the virus.
The administration of the quadrivalent dengue vaccine follows a specific procedural protocol to ensure efficacy and safety. The procedure begins with the healthcare provider verifying the patient's eligibility for vaccination, including assessing their medical history and any previous dengue infections. Following this, the provider prepares the vaccine for subcutaneous injection, ensuring that the vaccine is stored and handled according to the manufacturer's guidelines. The vaccine is administered in two doses, with the first dose given subcutaneously, typically in the upper arm or thigh, and the second dose administered three months later. It is crucial that the provider documents the administration details, including the date, site of injection, and any immediate reactions observed post-vaccination. This documentation is essential for tracking the patient's vaccination status and for any future medical needs.
After the administration of the quadrivalent dengue vaccine, patients are typically monitored for a short period to observe for any immediate adverse reactions. Common post-vaccination care includes advising the patient about potential side effects, which may include mild fever, soreness at the injection site, or fatigue. Patients should be informed about the importance of completing the two-dose schedule for optimal immunity. Additionally, they should be educated on the signs and symptoms of dengue fever and advised to seek medical attention if they experience any severe reactions or symptoms consistent with dengue infection. Follow-up appointments should be scheduled to ensure the second dose is administered within the recommended timeframe.
| Short Descr | DENGUE VACC QUAD 2 DOSE SUBQ | Medium Descr | DENGUE VACC QUAD LIVE 2 DOSE SCHEDULE SUBQ USE | Long Descr | Dengue vaccine, quadrivalent, live, 2 dose schedule, for subcutaneous use | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Non-Covered Service, not paid under OPPS | Type of Service (TOS) | 1 - Medical Care | Berenson-Eggers TOS (BETOS) | none | MUE | 1 |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2023-01-01 | Added | First appearance in Codebook. |
| 2022-07-01 | Added | Code added. Effective upon receiving emergency Use Authorization or approval from the FDA. |
| 2021-12-30 | Note | Published on AMA website. |
Get instant expert-level medical coding assistance.